Updates are available Correction dated 2021-05-19

Article History

Received: 16 July 2019

Revised: 14 March 2020

Accepted: 1 April 2020

First Online: 29 April 2020

Change Date: 19 May 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41416-021-01439-1

Ethics approval and consent to participate

: The study protocol was approved by each local institutional ethics committee (a list of the Ethics Committees that approved the study is available in S. , ) and conducted in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice and the Declaration of Helsinki. Written informed consent was obtained from all participants.

: No individually identifiable data is presented.

: Anonymised dataset may be available from the corresponding author on reasonable request.

: A.A. has received research grant support from BMS and Celgene; personal fees for serving in a consultant and/or advisory role for BMS, MSD and Boehringer; honoraria from Eli-Lilly and Pfizer. A.F. has received personal fees for serving in a consultant and/or advisory role for Novartis, Roche and Astrazeneca; honoraria from Novartis, Astrazeneca, Pfizer, Lilly, Eisai, Roche, Novartis and Celgene. L.C. has received personal fees for serving in a consultant and/or advisory role for Astrazeneca and Merck; honoraria from Celgene, Pfizer and Ipsen. The remaining authors declare no competing interests.

: The study was sponsored by Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) and partially supported by Celgene that provided investigational medicinal product and a restricted grant for the management of study procedures.